On October 10, Vall d’Hebron hosted the third annual meeting of the project RBDCOV (“RBD Dimer recombinant protein vaccine against SARS-CoV-2”). The objective of this initiative, in which the Infection and Immunity in Pediatric Patients group of the Vall d’Hebron Research Institute (VHIR) participates, is to test the efficacy, tolerability and safety of the HIPRA COVID-19 vaccine (BIMERVAX ®) in children and adolescents, and also in immunocompromised people. The project is part of the Horizon Europe program.
The meeting was the meeting point to establish the next steps regarding HIPRA vaccine research. At the same time, the provisional results of the study in immunosuppressed adults were presented, which confirm the safety and efficacy data of the vaccine also in this population, as well as the durability of the protection even against the viral variants that currently circulate in a majority. Regarding the study in pediatric and adolescent patients, recruitment data were presented that show a progressive increase in participants in the five participating centers.
“It is especially important to have data on the efficacy and safety of BIMERVAX® in the pediatric and adolescent population, which is why everyone involved in this study is making an effort to increase the recruitment of participants in order to reach the 300 individuals necessary to evaluate the results”says Dr. Pere Soler Palacín, head of the Pediatric Infectious Pathology and Immunodeficiencies Unit at the Vall d’Hebron University Hospital and the Infection and Immunity in Pediatric Patients group at the VHIR.
RBDCOV Project
RBDCOV is one of the projects that are committed to testing and continuing to advance with the new vaccine against COVID-19. To achieve this, companies and institutions from five European countries join forces to advance collaboratively. The project is led by the biotechnological pharmaceutical company HIPRA and has the participation of centers in Spain (Vall d’Hebron Research Institute, Irsicaixa, Fundación Lucha contra el SIDA (FLS), IDIBAPS, IDIBGI, ASPHALION, Vinces Consulting, Zabala Innovation) , United Kingdom (Veristat International), Italy (Fondazione Penta), Germany (European AIDS Treatment Group), and Turkey (Metpharm Arastirma Gelistirme Saglik Danismanlik). Specifically, Vall d’Hebron leads the study in minors.
Currently, the search is open for adolescents between 12 and 18 years old who want to participate in the clinical trial. Parents or guardians of minors interested in participating can contact the people responsible for the study by email or telephone:
2023-10-11 15:16:37
#Members #RBDCOV #project #meet #Vall #dHebron #advance #development #BIMERVAX #vaccine
